Given the strong anti-leukemic activity of these compounds, Menin inhibitors, including BN-104 (Revumenib), have demonstrated remarkable clinical efficacy in heavily pretreated relapsed or refractory (r/r) AML patients harboring KMT2A rearrangements or NPM1 mutations. Here, KMT2A is linked to acute myeloid leukemia.